
The highly anticipated Johnson & Johnson (NYSE:JNJ) merger with Synthes Inc. will have to wait another 60 days as the health care giants agreed to push back the "outside date" for sealing the deal.
The new agreement extends the contract period to June 25; the companies expect the deal to close in the 2nd quarter, according to an SEC filing.
The pair yesterday landed EuroZone regulatory approval to move forward with the merger.
It’s been a year since J&J’s CHF 159-per-share offer for the Swiss orthopedics giant. EU regulators expanded their probe into the deal last November, prompting J&J to seek ways to appease the commission.
Medtronic looks to stay ahead of liability issues
Med-tech titan Medtronic (NYSE:MDT) is looking to stay ahead of potential liability issues with a heightened focus on post-market surveillance of implanted medical devices.
Read more
Canaccord analyst hypes small med-tech
Canaccord Genuity analyst Jason Mills said he’s keeping an eye on Edwards Lifesciences (NYSE:EW), Thoratec (NSDQ:THOR) and AtriCure (NSDQ:ATRC).
Read more
Celeb scientist Robert Langer sells $480k of InVivo stock
MIT rock-star scientist Robert Langer cashed in $480,000 worth of InVivo Therapeutics (OTC:NVIV) stock, representing about 200,000 shares, leaving him with nearly 7.9 million shares – about a 12.4% stake in the regenerative medicine developer.
Read more
St. Jude has plans for India
St. Jude Medical (NYSE:STJ) promised to make more of its latest medical devices available in India, country manager Kaustav Banerjee told TwoCircles.net.
Read more
GPOs: Premier signs joint implant agreement with Biomet, Zimmer
Biomet Inc. and Zimmer (NYSE:ZMH) signed on to provide total joint implants to members of the Premier Healthcare Alliance.
Read more
- Boston Scientific enters into $2M senior unsecured credit facility
- TearLab launches underwritten IPO valued at $11.6 million
- Baxter (NYSE:BAX): Citi lowers price target from
$57 to $56, maintains "neutral" rating. Leerink Swann maintains "outperform" rating. - Boston Scientific (NYSE:BSX): Leerink Swann maintains "outperform" rating.
- Cynosure (NSDQ:CYNO): Leerink Swann maintains "outperform" rating.
- Intuitive Surgical (NSDQ:ISRG): JMP Securities raises price target from $560 to $650, maintains "outperform" rating.
- Insulet (NSDQ:PODD): Rodman & Renshaw raises to "outperform" rating.
- Solta Medical (NSDQ:SLTM): Leerink Swann maintains "outperform" rating.
- Syneron Medical’s(NSDQ:ELOS): Leerink Swann maintains "outperform" rating.